PSA velocity in conservatively managed BPH: Can it predict the need for BPH-related invasive therapy?

Prostate

Volumn 66, Issue 13, 2006, Pages 1407-1412

  Mochtar, Chaidir A ^a   Kiemeney, Lambertus A L M ^b   Pilar Laguna, M ^a   Debruyne, Frans M J ^b   De La Rosette, Jean J M C H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adrenergic alpha blockers; Benign prostatic hyperplasia; Prostate specific antigen; Treatment outcome

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN;

CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748474819     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20436     Document Type: Review

References (17)

1. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003;30(4):677-686.
2. Raaijmakers R, Wildhagen MF, Ito K, Paez A, de Vries SH, Roobol MJ, Schröder FH. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004;63(2):316-320.
3. Roobol MJ, Kranse R, de Koning HJ, Schröder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (ROTTERDAM). Urology 2004;63(2):309-313.
4. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125-135.
5. Roehrborn CG. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int 2004;93(Suppl 1):21-26.
6. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267(16):2215-2220.
7. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154(2 Pt 1):407-413.
8. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. Urology 1993;42(4):390-397.
9. Roehrborn CG, Pickens GJ, Carmody T III. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 1996;47(1):59-66.
10. Komatsu K, Wehner N, Prestigiacomo AF, Chen Z, Stamey TA. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996;47(3):343-346.
11. Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, deKernion JB. Serum prostate specific antigen levels after transurethral resection of prostate: A longitudinal characterization in men with benign prostatic hyperplasia. J Urol 1996; 156(3):1035-1039.
12. Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM, de la Rosette JJ. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 2005;65(2):300-305.
13. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coeffield S, Resnick M, Cook TJ, Waldstreicher J. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999;53(3):473-480.
14. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, Walsh PC. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 1995;45(4):591-596.
15. Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Natural history of PSA increase with and without prostate cancer. Urology 2003;62(1):64-69.
16. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB. Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. JAMA 2003;289(20):2695-2700.
17. Bruun L, Becker C, Hugosson J, Lilja H, Christensson A. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 2005;65(3):216-221.